Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1591-1600 of 3416 for cancer

Edit search filters
  1. A Study to Test Sacituzumab Govitecan Therapy in Patients with HER2-Negative Breast Cancer and Brain Metastases

    Rochester, MN

  2. A Study to Evaluate Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy for HER2+ Gastrointestinal Cancers

    Scottsdale/Phoenix, AZ

  3. Bevacizumab with or without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients with Recurrent Glioblastoma Multiforme

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  4. Venlafaxine in Preventing Chronic Oxaliplatin-Induced Neuropathy In Patients Receiving Combination Chemotherapy

    Rochester, MN

  5. Use of Navigator Echoes for 4D-MRI

    Rochester, MN

  6. Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)

    Jacksonville, FL

  7. Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

    Rochester, MN

  8. Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  9. Mayo Biopsy Marker

    Rochester, MN

  10. Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma

    Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer